Kenilworth-based Merck and Immune Design announced on Thursday the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design in a deal ...

Drugmaker Merck will acquire oncology company Immune Design for $300 million in cash. Immune Design is a late-stage immunotherapy company. The immunotherapy technology works by using a body’s immune ...

Merck & Co. is making a $300 million move to acquire Immune Design, developers of a midphase immunotherapy for non-Hodgkin’s lymphoma, as well as vaccines for respiratory syncytial virus and peanut ...

Merck & Co. Inc. (NYSE: MRK) announced that it will acquire late-stage immunotherapy company Immune Design (NASDAQ: IMDZ) for $300 million in cash. Per the deal, Merck through a subsidiary will ...

Feb 21 (Reuters) - Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs. Merck will pay $5.85 in cash ...